Associated tags: Lung cancer, TNG, Cancer, Euronext Paris, NEC, AI, Immunotherapy, Head, Corporation, Patient, Health care, MD
Locations: CA, ILLKIRCH GRAFFENSTADEN, FR, FRANCE, JAPAN
Retrieved on:
Wednesday, April 24, 2024
Strasbourg, France, April 24, 2024, 5:45 p.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies, announced that the documentation related to the Combined General Meeting (ordinary and extraordinary sessions) of Transgene’s shareholders is available.
Key Points:
- Strasbourg, France, April 24, 2024, 5:45 p.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies, announced that the documentation related to the Combined General Meeting (ordinary and extraordinary sessions) of Transgene’s shareholders is available.
- The notice of meeting, comprising the agenda and the draft resolutions was published in the Bulletin des Annonces Légales Obligatoires (BALO) n° 42 of April 5, 2024.
- These notices include information on how to attend and vote at the General Meeting.
- The General Meeting will be broadcast live on the Company’s website ( www.transgene.fr under “Investors - Shareholders’ Meeting”) and the video will also be available later within the time period provided for by the regulations.
PDT,
Chemoradiotherapy,
Head,
Disease,
Intelligence,
Patient,
Neoplasm,
Health care,
Cancer,
AI,
AACR,
NEC,
Curie Institute (Paris),
Euronext Paris,
Poster,
Corporation,
Neck,
Vaccine Extensive Phase I immunology data confirm strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers.
Key Points:
- Extensive Phase I immunology data confirm strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers.
- These data are highlighted in the AACR press conference being held today and in a poster presentation which will take place tomorrow, April 10, at 9:00 a.m. PDT.
- Key findings of the poster include:
All 16 patients who received TG4050 are disease free after a median 18.6-month follow-up.
- TG4050 is now starting to show a potential benefit for head and neck cancer patients at high risk of relapse.
Retrieved on:
Wednesday, March 27, 2024
MSD,
Research,
Conference call,
Conference,
Head,
AstraZeneca,
E7,
Patient,
Merck & Co.,
Tumor microenvironment,
Merck,
News,
R&I,
Cancer,
Virus,
MD,
E6,
Lung cancer,
AACR,
NEC,
European Journal,
HPV16,
Euronext Paris,
De novo,
Immune system,
ASCO,
Safety,
Poster,
Potyvirus,
Pharmaceutical industry Extended financial visibility secured until Q4 2025 through a revised credit facility provided by the major shareholder Institut Mérieux.
Key Points:
- Extended financial visibility secured until Q4 2025 through a revised credit facility provided by the major shareholder Institut Mérieux.
- “During 2023 Transgene continued to make significant progress, delivering compelling data that confirm the value of our approach to treating cancer using our novel immunotherapies” commented Dr. Alessandro Riva, MD, Chairman and CEO of Transgene.
- As announced on May 5, 2023, AstraZeneca terminated its oncolytic virus research and development collaboration with Transgene following a strategic review of its pipeline.
- In 2024, Transgene expects to communicate progress and significant results and readout on all of its clinical stage assets.
Retrieved on:
Wednesday, March 27, 2024
Communication,
Culture,
CNAM,
Corporate communication,
CFO,
École,
Knowledge,
Sciences Po,
Political science,
Executive Committee,
Cancer,
MD,
Euronext Paris,
Management Lucie contributed significantly to the smooth execution of four successful securities transactions, as well as to strengthening the external visibility of Transgene.
Key Points:
- Lucie contributed significantly to the smooth execution of four successful securities transactions, as well as to strengthening the external visibility of Transgene.
- Alongside this new appointment, Transgene has promoted Christelle Schwoerer to Chief Human Resources Officer, effective from April 1, 2024, and she also joins the Executive Committee.
- Christelle Schwoerer joined Transgene’s Human Resources department in 2013, and her knowledge of the organization, its culture and its employees are real assets in her new, expanded role.
- Christelle Schwoerer holds a Master 1 in human resources from the CNAM Grand-Est and a Master 2 in management and human resources from the Ecole de Management de Strasbourg, which she obtained in 2020 and 2021, respectively.
TRANSGENE (Paris: TNG) today announces that Management will participate in several investor events in the upcoming months, as set out below.
Key Points:
TRANSGENE (Paris: TNG) today announces that Management will participate in several investor events in the upcoming months, as set out below.
Van Lanschot Kempen Life Sciences Conference (Amsterdam, Netherlands): April 16, 2024,
Oddo BHF Nextcap Forum (virtual): June 6, 2024.
Strasbourg, France, March 6, 2024, 7:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present a poster on updated data from the ongoing randomized Phase I trial of TG4050 at the American Association for Cancer Research Annual Meeting (AACR).
Key Points:
- Strasbourg, France, March 6, 2024, 7:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present a poster on updated data from the ongoing randomized Phase I trial of TG4050 at the American Association for Cancer Research Annual Meeting (AACR).
- The AACR will take place in San Diego, California, USA, from April 5 to 10, 2024.
- The abstract will be available on the AACR website April 5, 2024, at 3:00 p.m.
- Transgene and NEC plan to continue the development of TG4050 in this indication with a Phase II extension of the trial expected to start in 2024.
Head,
Neoplasm,
Immune system,
NEC,
AI,
MD,
Immunotherapy,
TME,
NGS,
Health care,
Patient,
Corporation,
Euronext Paris,
Cancer,
Partnership,
Pharmaceutical industry BostonGene is partnering with NEC and Transgene to continue performing tumor molecular profiling and microenvironment analysis and provide high-throughput sequencing services.
Key Points:
- BostonGene is partnering with NEC and Transgene to continue performing tumor molecular profiling and microenvironment analysis and provide high-throughput sequencing services.
- The partnership with BostonGene will enable fast turnaround of next-generation sequencing (NGS) data, and sophisticated analytics will enable comprehensive profiling of patient immune contexture.
- “Our collaboration with BostonGene has provided in-depth information on patient phenotypes in the Phase I trial.
- “We are committed to supporting Transgene and NEC as they advance these clinical trials,” said Nathan Fowler, MD, Chief Medical Officer at BostonGene.
MD,
International,
TCR,
Knowledge,
CBO,
Syneos Health,
University,
Cancer,
Bachelor,
Business development,
MBA,
Euronext Paris,
IMD,
Doctor of Philosophy,
Management development,
Health Strasbourg, France, January 22, 2024, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to announce the appointment of James Wentworth, PhD, MBA, as Chief Business Officer (CBO) and member of the executive management team, effective immediately.
Key Points:
- Strasbourg, France, January 22, 2024, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to announce the appointment of James Wentworth, PhD, MBA, as Chief Business Officer (CBO) and member of the executive management team, effective immediately.
- Dr. Wentworth will be responsible for developing, leading, and implementing Transgene’s business, corporate development and partnering strategies.
- He joins Transgene following increasing responsibility spanning business development, strategy and commercial roles.
- Dr. James Wentworth, Chief Business Officer, said: “It is an honor to be joining Transgene at this exciting time and to work alongside the outstanding executive team to contribute to Transgene’s success.
TRANSGENE (Paris: TNG) today announced its financial reporting dates for 2024.
Key Points:
TRANSGENE (Paris: TNG) today announced its financial reporting dates for 2024.
Health care,
ASCO,
Euronext Paris,
Cancer,
Head,
JST,
AI,
NEC,
Patient,
Corporation,
Vaccine Based on promising data obtained in the Phase I[*] trial ( NCT04183166 ), Transgene and NEC are preparing a randomized Phase I/II extension of this trial slated to start in 2024.
Key Points:
- Based on promising data obtained in the Phase I[*] trial ( NCT04183166 ), Transgene and NEC are preparing a randomized Phase I/II extension of this trial slated to start in 2024.
- Transgene and NEC expect to present additional immunological and clinical data from the Phase I trial at a scientific conference in the first half of 2024.
- We are looking forward to continuing to treat patients in our clinical studies with our individualized cancer vaccine TG4050.
- Our joint clinical development plan builds on these promising data in a setting where there is no approved treatment to prevent patient relapse after adjuvant chemoradiotherapy.
